Search - Inserm - Institut national de la santé et de la recherche médicale Access content directly

Filter your results

5 Results
authFullName_s : Jérôme Giustiniani
Image document

A novel VEGF-independent antiangiogenic therapy targeting the CD160 receptor

Philippe Le Bouteiller , Julie Tabiasco , Jérôme Giustiniani , Armand Bensussan
Médecine/Sciences, 2012, 28 (1), pp.37-38. ⟨10.1051/medsci/2012281013⟩
Journal articles inserm-02168009v1
Image document

Identification and characterization of a transmembrane isoform of CD160 (CD160-TM), a unique activating receptor selectively expressed upon human NK cell activation.

Jérôme Giustiniani , Armand Bensussan , Anne Marie-Cardine
Journal of Immunology, 2009, 182 (1), pp.63-71
Journal articles inserm-00352331v1
Image document

Anti-CD160, Alone or in Combination With Bevacizumab, Is a Potent Inhibitor of Ocular Neovascularization in Rabbit and Monkey Models

Thierry Menguy , Anne Briaux , Elisabeth Jeunesse , Jérôme Giustiniani , Alexandre Calcei , et al.
Investigative Ophthalmology & Visual Science, 2018, 59 (7), pp.2687-2698. ⟨10.1167/iovs.18-24024⟩
Journal articles hal-03379522v1
Image document

Chemotherapy treatment induces an increase of autophagy in the luminal breast cancer cell MCF7, but not in the triple-negative MDA-MB231

Christian Garbar , Corinne Mascaux , Jérôme Giustiniani , Yacine Merrouche , Armand Bensussan
Scientific Reports, 2017, 7, ⟨10.1038/s41598-017-07489-x⟩
Journal articles hal-03424972v1
Image document

The IL-17B-IL-17 receptor B pathway promotes resistance to paclitaxel in breast tumors through activation of the ERK1/2 pathway

Emilie Laprevotte , Stéphanie Cochaud , Stanislas Du Manoir , Marion Lapierre , Cécile Dejou , et al.
Oncotarget, 2017, 8 (69), ⟨10.18632/oncotarget.23008⟩
Journal articles hal-02382938v1